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patients with chronic pain in primary care
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Abstract
Background: There is increasing concern among primary care practitioners about the use of opioids for chronic pain, including their
adverse effects, but little attention has been given to how reports of side effects from prescription medication can contribute to
outcomes among patients with chronic pain. The aim of this study was to investigate the impact of frequently reported side effects
on mood, disability, and opioid misuse in patients with chronic pain prescribed opioids within primary care.
Methods: Two hundred (N 5 200) patients with chronic pain taking opioids for pain were recruited into the study. All patients
completed baseline measures and a monthly side effects checklist once a month for 6 months. Patients were divided evenly based
on a median split of the number of endorsed side effects over 6 months. The subjects repeated the baseline measures at the end of
the study period.
Results:Over time, reports of medication side effects tended to decrease, but differences in frequency of reported side effects from
baseline to follow-up (6-month time) were not significant, and the order of the frequency of the reported side effects remained
similar. Patients who reported significant medication-related adverse effects reported significantly greater activity interference,
negative affect, and catastrophizing compared with those with fewer side effects (P , 0.01). In addition, those patients with pain
who reported more side effects showed significantly higher scores on opioid misuse risk (P , 0.001).
Discussion: This study demonstrates the important role of monitoring medication-related side effects among patients with chronic
pain who are prescribed opioid medication for pain within primary care.
Keywords: Side effects, Opioids, Primary care, Pain management, Chronic pain, Side effects, Medication misuse
1. Introduction
Chronic pain is a significant public health–related problem that
negatively impacts quality of life among millions of individuals and
costs society an estimated $560 to $635 billion annually.21 Pri-
mary care providers often face challenges related to undertreated
pain and the need to prescribe opioids for their patients who
report severe debilitating pain. However, there are also ongoing
concerns about misuse, abuse, and addiction related to use of
opioids for chronic noncancer pain. With increased availability of
opioids over the past decade, prescription drug abuse has been
perceived to be a fast-growing problem,13 and the co-occurrence
of prescription opioid misuse and chronic pain has become very
common.10,32 Fear of regulatory scrutiny about improper pre-
scribing practices associated with opioids is also a primary
concern among prescribing physicians. This has resulted in
tension between the need to treat legitimate medical conditions,
such as postoperative pain and failed surgery, while also
minimizing the risk of opioid abuse and addiction. According to
provider survey studies, more than one-half of physicians
surveyed reported that they were worried about scrutiny re-
garding opioid prescribing,19 and potential professional sanc-
tions.27 The safe use of opioids for treatment of chronic pain has
become a particular concern among health care providers and
a high priority had been place on the identification of those who
are at the greatest risk of opioid misuse.25
All prescription medications have the potential for associated
side effects, and the monitoring of side effects is clinically
important. Ingesting medications can add to risk of unintended
consequences, which can be mild without any long-term effects
(eg, fatigue) or, in some situations, quite severe (eg, gastrointes-
tinal bleeding, heart, and liver disease). Although certain
medication side effects may have perceived beneficial qualities
(eg, weight loss), most are unwanted and can interfere with overall
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quality of life including headaches, nausea, dizziness, constipa-
tion, and weakness. Also, some medications, that are proven to
be helpful in treating a certainmedical condition, are discontinued
because they cannot be tolerated because of their side effects.
Studies have examined the effect of medication-related side
effects among patients with chronic pain on treatment satisfac-
tion,16,18,28 but few studies have investigated the influence of
medication side effects on pain-related outcomes among
patients with chronic pain. The bulk of previous studies
conducted in this area primarily examined the influence of
medication side effects on patients’ daily functioning or quality
of life. Martel et al.29 showed that medication side effects were
associated with heightened pain-related activity interference
among patients treated in specialized, tertiary care pain clinics.
To our knowledge, such studies have yet to be conducted among
patients with pain seen in primary care settings.
The aim of our study was to extend previous work by exploring
the influence of medication side effects on mood disorder,
negative affect, and opioid misuse among primary care patients
with chronic pain. We hypothesized that patients who reported
experiencing many medication-related side effects would show
greater pain intensity and pain-related disability, higher emotional
distress, and possibly higher risk of opioid misuse compared with
those who reported fewer medication-related side effects.
2. Methods
This study was approved by the institutional review boards (IRBs)
of each of the participating health care organizations and centers,
and informed consent was obtained from all the participants
before any study procedure.
We identified and recruited patients who had a diagnosis of
chronic pain from primary care centers located within the
Metropolitan Boston area as part of a larger study.27 Subjects
were included if they (1) had chronic pain for .6 months’
duration, (2) averaged 4 or greater on a pain intensity scale of 0 to
10, (3) were able to speak and understand English, (4) had been
prescribed or were eligible to be prescribed opioid therapy for
pain based on the practitioner’s personal criteria for eligibility for
chronic opioid therapy, and (5) were under the care of a primary
care physician.
Patients were excluded from participation if they meet any of
the following criteria: (1) diagnosis of cancer or any other
malignant disease, (2) acute osteomyelitis or acute bone disease,
(3) present or past DSM-IV diagnosis of schizophrenia, delusional
disorder, psychotic disorder, or dissociative disorder that would
be judged to interfere with study participation, (4) pregnancy, (5)
any clinically unstable systemic illness judged to interfere with
treatment, (6) a pain condition requiring urgent surgery, and (7) an
active substance use disorder, such as cocaine or IV heroin use
(positive on theMINI International Neuropsychiatric Interview;M.I.
N.I. v.5.0),26 that would interfere with study participation.
Patientswere recruited through flyers placed in the centers and
were invited to participate by their treating physicians. Patients
were followed up with a letter describing the study and an
informed consent form that they were instructed to complete and
mail back to the research assistant assigned to this study. All
patients received a $50 gift card for completing the packet of
questionnaires at the start of the study. Patients were informed
that they would be called each month to obtain information about
their health status over 6 months, to track their medication use,
and to determine the presence of any side effects related to their
medication. They were informed that information from the study
would be shared with their practitioners, but that their information
was protected through the guidelines of a confidentiality certif-
icate through the National Institutes of Health (NIH; www.nidcr.
nih.gov) as a research participant and that personal identifiable
information would be protected from disclosure.
2.1. Baseline measures
After providing consent, patients were asked to complete the
following self-report questionnaires:
2.1.1. Demographic questionnaire
This baseline questionnaire collected basic demographic in-
formation about the patients, including age, sex, racial back-
ground, education level, marital status, history of medical
problems, history of psychiatric treatment, and disability or
worker’s compensation status.
2.1.2. Side effects checklist
This 12-item checklist was adopted from the original 20-item side
effects checklist (SEC)22 and created based on the most
frequently described adverse effects of opioids. All participants
were asked whether they had experienced any of the following 12
side effects over the past month: constipation, dizziness, dry
mouth, headache, itching, confusion, nausea, nightmares,
sneezing, sweating, visual problems, weakness, or any other
unnamed side effects. Patients were not asked to provide ratings
of medication side effects based on a specific medication, but
rather based on all the medications that they were taking. The
SEC is similar to other self-report measures of medication side
effects that have been used in previous studies.20,28
2.1.3. The Brief Pain Inventory
The Brief Pain Inventory (BPI) is a well-known measure of clinical
pain.11 The questionnaire provides information about pain
history, intensity, and location as well as the degree to which
the pain interferes with daily activities, mood, and enjoyment of
life. Scales (rated from 0 to 10) indicate the intensity of pain in
general, at its worst, at its least, and pain “right now.” Test–retest
reliability for the BPI reveals correlations of 0.93 for worst pain,
0.78 for usual pain, and 0.59 for pain now. Research suggests
that the BPI has adequate validity.11
2.1.4. The Pain Disability Index
This inventory consists of 7 questions designed to measure the
degree towhich patients believe that their pain interferes with their
functioning in family and home responsibilities, recreation, social
activities, occupation, sexual behavior, self-care, and life-support
(eating and sleeping) activity.35 Patients respond to each item on
0- to 10-point scales anchored with descriptors ranging from “no
disability” to “total disability.” This measure has adequate internal
consistency (Cronbach alpha 5 0.86) and test–retest reliability
(0.91) and is a valid measure of disability.35
2.1.5. The Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) is a 14-item
scale designed to assess the presence and severity of anxious
and depressive symptoms.37 Seven items assess anxiety, and 7
items measure depression, each coded from 0 to 3. The HADS
has been used extensively in clinics and has adequate reliability
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(Cronbach Alpha 5 0.83) and validity, with optimal balance
between sensitivity and specificity.2 It has been translated into
many languages and is widely used around the world in clinical
and research settings.
2.1.6. Pain Catastrophizing Scale
The Pain Catastrophizing Scale (PCS) is a 13-item instrument that
examines 3 components of catastrophizing: rumination, magni-
fication, and helplessness. The PCS is found to predict levels of
pain and distress among clinical patients, and scores have been
related to thought intrusions.33,34 It has good psychometric
properties with adequate reliability and validity and is associated
with levels of pain, depression, and anxiety.
2.1.7. Screener and Opioid Assessment for Patients with
Pain-Revised
The Screener and Opioid Assessment for Patients with Pain-
Revised (SOAPP-R) is a 24-item, cross-validated, self-
administered screening instrument revised from the original
SOAPP v.16,7 used to help determine risk potential for aberrant
drug-related behavior. Items are rated from 05 never to 45 very
often, and their sum is the total SOAPP-R score. The SOAPP-R
has been shown to have good predictive validity, with an area
under the curve ratio of 0.88 (95% confidence interval [CI],
0.81–0.95). Test–retest reliability was 0.71with a coefficient alpha
of 0.74. A cutoff score of 18 shows adequate sensitivity (0.86) and
specificity (0.73) and has been cross-validated.4
2.2. Follow-up measures
Each month, patients were called and asked to complete the
same items from the SEC over the phone. After 6 months, all
subjects were asked to repeat the baseline measures of the BPI,
HADS, Pain Disability Index and the Current Opioid Misuse
Measure (COMM).5 The COMM is a 17-item self-reported
questionnaire designed to assess current aberrant medication-
related behaviors during opioid treatment. All items are rated from
0 5 never to 4 5 very often, with a total maximum score of 68.
Construct validity has been shown to be adequate, with positive
correlates with urine toxicology results (P , 0.05). Test–retest
reliability was 0.86 with a 95% CI ranging from 0.77 to 0.92. The
overall accuracy of the COMM for predicting current aberrant
drug-related behavior, as measured by the area under the curve
ratio, was 0.81 (95% CI, 0.74–0.86; P, 0.001), and coefficient a
(0.86) for the 17 items suggests adequate reliability. A cutoff score
of 8 yielded a sensitivity of 0.75 and specificity of 0.65.
Patients were paid $50 once the completed follow-up packet
of questionnaires was received. Packets were resent if they were
not received within a month of the mailing, and all patients were
called to verify that they had received the second packet of
questionnaires.
2.3. Statistical analyses
Analyses were conducted using SPSS (IBM, version 22.0).
Descriptive data for continuous variables were presented as
mean values and SDs, and data for categorical variables were
presented as percentages. Total scores and average values were
calculated for the baseline measures and follow-up measures.
Both parametric (t test) and nonparametric analyses (x2 or
Wilcoxon Signed Rank tests) were used to compare results
depending on the variables, with 2-sidedP values set atP, 0.05.
3. Results
3.1. Descriptive data
Altogether, 12 primary care centers and 200 patients with chronic
pain located within the metropolitan Boston area were recruited
for this study. Of all the patients (N 5 200), 60.0% were women,
and most were Caucasian (72.4%). Although most subjects had
back or neck pain, only 8 percent reported having low back pain
alone. A great majority of the patients (74.5%) reported having
multiple pain sites. One hundred ninety-four (97.0%) of the
patients reported taking prescription opioids at the start of the
study. Six patients, who were initially not taking prescription
opioids, were prescribed opioids for pain during the 6-month
study trial. Of those patients prescribed opioids at baseline,
59.2% were prescribed short-acting opioids alone (oxycodone
60.1%, hydrocodone 23.0%, hydromorphone 10.8%, morphine
3.4%, codeine 2.7%), 16.0% were prescribed extended-release,
long-acting opioids alone (methadone 35.2%, oxycodone
28.1%, morphine 25.4%, and transdermal fentanyl 11.3%),
24.5% were prescribed both short-acting and extended-
release, long-acting opioids, 7.5% were prescribed tramadol,
and 2.1% were prescribed buprenorphine and naloxone alone.
Other nonopioid prescription medications and the number of
subjects taking them included anticonvulsants (14.5%; N 5 29),
nonsteroidal anti-inflammatory drugs (6.0%; N 5 12), antide-
pressants (5.0%; 5.0%), muscle relaxants (4.0%; N 5 8), and
anxiolytics and sedatives (2.0%; N5 4). Four subjects were using
lidocaine, one was using benadryl, and one was taking Marinol.
We did not track intake of nonprescription medication.
The frequency of reported medication side effects was
averaged, for each patient, across the 6-month period. All
patients were then grouped as “high” or “low” in medication side
effects based on a median split (median 5 2.33). The mean
number of side effects was 2.85 (62.33, range 0.0–11.33) over
a 6-month period. Patients were divided based on a median split,
and those reporting less than an average of 2.33 side effects were
classified as having few side effects (N 5 99, mean 5 1.00 6
0.71, median5 1.00, range 0.0–2.25), and those reporting equal
to or greater than 2.33 side effects each month were classified as
having many side effects (N5 101, mean5 4.666 1.90, median
4.17, range 2.33–11.33). As can be seen from Table 1, adverse
effects associated with prescription medication were identified
with the highest being dry mouth (49.0%), constipation (36.7%),
sweating (31.1%), itching (28.1%), headache (27.6%), and
weakness (27.6%).
Over time, reports of medication side effects tended to
decrease, but differences in frequency of reported side effects
from baseline to follow-up (ie, 6-month time point) were not
significant. Dry mouth, constipation, sweating, headache, and
weakness continued to be associated with taking prescription
medication. The order of the frequency of the reported side
effects remained similar between those with many side effects
and those with few side effects, although those classified as
having few side effects reported experiencing weakness,
headache, and dizziness much less often.
3.2. Correlates of medication side effects at baseline
Patients with “high” and “low” medication side effects did not
differ significantly in terms of age, sex, ethnicity, pain site, pain
intensity, and pain relief (Table 2). However, patients reporting
high medication side effects scored significantly higher on
measures of activity interference (P , 0.05), disability (P ,
0.05), catastrophizing (P , 0.01), and on the HADS anxiety
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subscale (P , 0.05) compared with those with low side effects.
Patients with a higher frequency of self-reported side effects also
scored significantly higher on the SOAPP-R (P, 0.001; Table 3).
3.3. Correlates of medication side effects over time
Based on the telephone interview data at 6 months after start of
the study, average pain scores among all the subjects remained
relatively constant (before 5 7.0 6 1.9, after 5 6.7 6 2.0), and
most continued to report above average activity interference
(daily routine before5 6.86 2.6/10, after5 6.76 2.5/10). At 6-
month follow-up, those patients with chronic pain who reported
a higher number of average side effects again tended to report
significantly more activity interference compared with those who
reported a lower number of side effects (Table 4). Significant
differences were also found between those patients with chronic
pain classified as experiencing few side effects compared with
those reporting many side effects with higher scores among
those with a higher number of side effects on mood (HADS total
P , 0.01), pain catastrophizing (P , 0.001), disability (Pain
Disability Index P , 0.001), and opioid misuse (COMM; P ,
0.001; Table 4).
4. Discussion
This prospective secondary data analyses study was designed to
determine how reports of medication-related side effects over 6
months were associated with disability, mood, and opioid misuse
among patients with chronic pain on opioid therapywithin primary
care. Our main findings showed that patients who reported
experiencing many side effects from their medication showed
greater activity interference, negative affect, and greater cata-
strophizing than those reporting a lower number of side effects.
Another important finding of this study was that patients who
were more prone to misuse opioids reported more adverse
effects of the medication. It might be predicted that those who
would overuse or misuse opioids would report fewer side effects
of opioids because they would like taking opioids, which is in
Table 1
Comparisons on side effect checklist response percentages between baseline (N 5 200) and 6-month follow-up (N 5 172), and
comparisons between those reporting many side effects and those reporting few side effects at baseline and at follow-up.
Variable Total baseline
(N 5 200)
6-month follow-up
(N 5 172)*
Baseline high
side effects
(n 5 101)
Baseline low
side effects
(n 5 99)
6-month high
side effects,
(n 5 84)
6-month low
side effects
(n 5 88)
Side effects (% yes)
Dry mouth 49.0 48.6 68.0 29.2† 74.4 23.6†
Constipation 36.7 35.0 53.0 19.8† 60.0 12.0†
Sweating 31.1 31.6 44.0 17.7† 56.5 8.7†
Itching 28.1 20.3 42.0 13.5† 32.9 8.7†
Headache 27.6 29.4 46.0 8.3† 47.1 13.0†
Weakness 27.6 24.3 45.0 9.4† 43.5 6.5†
Dizziness 19.4 15.8 36.0 2.1† 31.8 1.1†
Nausea 18.9 18.1 26.0 11.5‡ 29.4 7.6†
Confusion 14.3 10.2 26.0 2.1† 20.0 1.1†
Visual problem 12.8 14.1 10.7 2.1† 25.9 3.3†
Nightmares 10.7 9.6 10.7 2.1† 18.8 1.1†
Sneezing 8.2 9.0 6.1 2.0§ 17.6 1.1†
* None of the differences between baseline and follow-up were significant.
† P , 0.001.
‡ P , 0.01.
§ P , 0.05.
Table 2
Baseline demographic andpain description itemsand comparisonbetweenpatientswithmany side effects (mean5 4.66,median5 4.17,
n 5 101) and patients reporting few medication-related side effects (mean 5 1.00, median 5 1.00, n 5 99).
Variable Total (N 5 200) High side effects (n 5 101) Low side effects (n 5 99) P
Age 53.6 6 10.7 52.1 6 11.2 54.3 6 10.3 NS
Sex (% female) 60.0 58.4 61.6 NS
Ethnicity (%)
Caucasian 72.4 68.0 76.8 NS
African American 17.1 21.0 13.1 NS
Hispanic 9.0 10.0 8.1 NS
Other 1.5 1.0 2.0 NS
Pain site (% yes)
Low back 8.2 9.2 7.1 NS
Multiple sites 74.5 73.5 75.5 NS
Pain intensity (past 24 h)
Worse 8.2 6 1.7 8.3 6 1.6 8.1 6 1.9 NS
Least 5.0 6 2.4 5.1 6 2.4 4.8 6 2.3 NS
Average 6.3 6 1.7 6.4 6 1.7 6.1 6 1.8 NS
Now 6.5 6 2.3 6.6 6 2.4 6.3 6 2.3 NS
Pain relief % (24 h; 0–100) 54.2 6 23.9 52.3 6 24.8 56.0 6 22.9 NS
*P , 0.05.
NS, nonsignificant.
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agreement with past studies that show that opioid liking predicted
misuse.3,30 However, all patients in this study had been taking
opioids for over 6months andwould likely not report any euphoria
related to taking pain medication. Instead, these findings seem to
support an association of sensitivity to medications with
functional limitations, mood disorder, and opioid misuse. These
results also emphasize the importance of attending to patient
reports of adverse effects from taking prescription medication as
a prediction of future problematic outcomes. These findings are in
agreement with studies using quantitative sensory testing which
show that those who are hyperalgesic also are prone to misuse
opioids.15 This study suggests that those with opioid misuse risk
are sensitive to reactions of medications as well.
Most prescription medications have associated adverse
effects, and it is common for users of opioids to report dry
mouth, constipation, and itching, among other symptoms.
However, these findings have clinical implications for assessment
and treatment of patients with chronic pain in primary care. In
agreement with findings among patients in specialty pain
centers,29 those who report more medication-related side effects
present with a disposition toward future problems. Patients with
pain who have a significant mood disorder, who catastrophize,
and who are more disabled due to their pain tend to ruminate
about pain and may tend to focus on symptoms and experience
helplessness when in pain. There is evidence that patients who
demonstrate the most emotional distress are prone to be
prescribed opioids for pain.8,24 It should also be pointed out that
despite taking opioids for pain, many of the patients reported
significant pain and disability. Past research indicates that those
with greater negative affect tend not to benefit from opioids.23,36
Thus, the long-term benefit of prescribing opioid therapy for any
patient who presents with high levels of medication-related side
Table 3
Baseline comparison questionnaire scores between those reportingmanymedication-related side effects (n5 101) and those reporting
few medication-related side effects (n 5 99).
Variable Total (N 5 200) High side effects (n 5 101) Low side effects (n 5 99) P
Interference*
Routine daily 6.9 6 2.5 7.4 6 2.3 6.3 6 2.6 t 5 3.2†
Social 6.6 6 2.9 7.1 6 2.6 6.1 6 3.0 t 5 2.7†
Outdoor/rec 7.1 6 2.8 7.7 6 2.4 6.5 6 3.0 t 5 3.0†
Sleep 6.5 6 3.2 7.4 6 2.7 5.5 6 3.4 t 5 4.3‡
Appetite 4.0 6 3.3 4.6 6 3.0 3.3 6 3.4 t 5 3.9‡
Work 7.3 6 2.7 7.1 6 2.5 6.6 6 3.0 t 5 4.4‡
Mood 6.4 6 2.7 7.1 6 2.5 5.6 6 2.6 t 5 4.4‡
Pain Disability Index (PDI-Total) 44.0 6 15.3 46.5 6 12.3 41.4 6 17.6 t 5 2.2§
PCS 25.6 6 12.5 28.1 6 12.1 23.0 6 12.4 t 5 2.8†
Hospital Anxiety and Depression Scale (HADS)
Anxiety 9.5 6 4.4 10.1 6 4.1 8.9 6 4.5 t 5 2.0§
Depression 9.0 6 4.6 9.4 6 4.3 8.5 6 4.7 NS
Total score 18.4 6 7.9 19.5 6 7.2 17.3 6 8.4 NS
SOAPP-R 22.4 6 11.3 25.1 6 11.6 19.5 6 10.4 t 5 3.6‡
* 0–10 scale; 0 5 no interference; 10 5 extreme interference.
† P , 0.01.
‡ P , 0.001.
§ P , 0.05.
PCS, Pain Catastrophizing Scale; PDI, Pain Disability Index; SOAPP-R, Screener and Opioid Assessment for Patients with Pain-Revised.
Table 4
Follow-upquestionnaires comparisonscoresbetween those reportingmanymedication-related side effects (n5 84) and those reporting
few medication-related side effects at 6 months (n 5 88).
Variable All patients (N 5 172) High side effects (n 5 84) Low side effects (n 5 88) P
Interference*
Routine daily 6.7 6 2.6 7.3 6 2.4 6.1 6 2.6 t 5 3.1†
Social 6.5 6 3.0 7.2 6 2.6 5.9 6 3.2 t 5 2.9†
Outdoor/rec. 7.0 6 2.8 7.3 6 2.6 6.6 6 2.9 NS
Sleep 6.2 6 3.1 6.9 6 2.6 5.7 6 3.4 t 5 2.9†
Appetite 4.4 6 3.3 4.9 6 3.3 3.9 6 3.2 t 5 2.1‡
Work 6.8 6 3.0 7.8 6 2.4 5.9 6 3.1 t 5 4.7§
Mood 6.2 6 2.7 6.9 6 2.5 5.5 6 2.8 t 5 3.6§
HADS anxiety 9.3 6 4.5 10.1 6 4.1 8.5 6 4.7 t 5 2.3‡
HADS depression 9.3 6 4.2 10.4 6 3.4 8.2 6 4.7 t 5 3.4†
HADS total 18.5 6 7.7 20.4 6 6.5 16.7 6 8.3 t 5 3.1†
PCS 23.1 6 13.6 27.6 6 13.3 18.6 6 12.5 t 5 4.4§
PDI 43.9 6 16.0 49.3 6 10.6 38.5 6 18.6 t 5 4.4§
COMM 10.1 6 8.2 12.9 6 9.2 7.5 6 6.2 t 5 4.3§
* 0–10 scale; 0 5 no interference; 10 5 extreme interference.
† P , 0.01.
‡ P , 0.05.
§ P , 0.001.
COMM, Current Opioid Misuse Measure; HADS, Hospital Anxiety and Depression Scale; PCS, Pain Catastrophizing Scale; PDI, Pain Disability Index.
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effects should be examined. However, contrary to our hypoth-
esis, no differences were found in pain intensity between those
who reported experiencing more medication-related side effects
and those with fewer side effects. Thus, reports of side effects are
not just related to reports of general hypersensitivity. Future
studies are needed to help understand this negative finding.
It is interesting that, in general, those who scored higher on the
PCS reported a higher incidence of adverse effects to pre-
scription medication. By definition, those who catastrophize and
have recurrent worried thoughts tend to focus on symptoms and
be hypervigilant to new sensations. Whether the higher incidence
of reported side effects was related to heightened attention to
physical symptoms or whether persons who tend to catastroph-
ize have a physical predisposition that may make them more
susceptible to adverse effects of medication needs to be
addressed in future investigations. Because those who cata-
strophize have been found to be hyperalgesic based on
quantitative sensory testing,14 there is support to suggest that
these individuals may also have a heightened sensitivity to
adverse reactions to medication. Future research may focus on
objective assessment of differences in physical reactions to
medications based on the level of catastrophizing.
There has been a recent change in attitudes among providers
toward the use of chronic opioid therapy to treat noncancer pain.
This has been particularly notable among younger primary care
practitioners (PCPs).24,27 Recent guidelines have encouraged
increased emphasis on educating PCPs on issues of chronic pain
and substance abuse.31 Although opioids will continue to be
offered for acute pain management, there is less willingness to
sustain patients on chronic opioid therapy. Centers for Disease
Control (CDC) guidelines encourage risk assessment, periodic
urine screens, consultation with prescription monitoring pro-
grams, opioid agreements, and frequentmonitoring of all patients
prescribed opioids for pain.9 As this study suggests, assessment
of medication-related side effects would also be valuable as
a predictor of future opioid misuse.1 Regular adherence
monitoring by clinicians may further assist in preventing physical
and psychological toxicity such as drug abuse and addiction.17
This study has a number of limitations that should be
highlighted when interpreting these results. First, we did not
relate the specific side effects to the specific drugs taken for pain,
andwe did not collect medication dosage. It is possible that those
who reported more side effects were taking higher doses of
medication. We also monitored side effects as either present or
absent, and did not assess the intensity of each of the side effects
that were experienced. It might be shown that the severity of the
side effects may have more predictive power than the total
number of the side effects experienced. It is also possible that
some of the reported side effects may have already been present
before taking opioids, and scores on the SEC may not represent
adverse reactions only to prescription medications. Most of the
items on the SEC represent somatic symptoms, and this
checklist may well be measuring somatic complaints. Future
investigations might consider teasing out this relationship by
including measures that assess multiple physical symptoms12
and by obtaining side effect reports before the subjects are
prescribed opioids. Second, although this is a longitudinal study,
we also cannot assume that the outcomes at 6 months followed
a progression from baseline. Close monitoring with daily assess-
ments might help to address this study limitation. Third, this study
was conducted in an urban area in the northeast region of the
United States, and it is uncertain whether these results might be
affected by selection bias based on willingness to participate or
by regional differences. Although some patients dropped out
before completing the study, which could have contributed to
selection bias, we did not find differences among those who
completed the 6-month trial and those who did not. Fourth, the
assessments were all self-report measures and objective
measures of function or opioid compliance were not included.
We did not capture the participants’ duration of pain and the
duration of using opioids. Although validated measures were
used to assess opioid risk and misuse, the results were based on
self-report. Future studies would benefit from results of urine
toxicology screens and provider ratings of compliance. Also,
many measures were included in the study, and it is possible that
some results would be significant by chance alone. Finally, it
should be noted that these results are correlational and do not
assume causation.
Despite these limitations, the results of this study emphasize
the importance of monitoring adverse effects of prescription
pain medication and provide some insight into possible
psychosocial risk factors of poor outcome in treating patients
with chronic pain. This study is also notable because it is the first
to demonstrate that primary care patients who report a greater
number of side effects, possibly related to opioid use, may be at
greater risk of medication misuse. Our study is one of the few
that have been conducted to assess the relationship between
opioid use, side effects, and psychosocial factors in primary
care. Managing complex pain patients in primary care settings
can be extremely challenging. PCPs typically have limited time,
training, and resources to effectively evaluate patients with
chronic pain. These findings have clinical implications that
support the benefits of carefully monitoring reports of side
effects of patients who are prescribed opioids in primary care
centers. This might have a positive effect in reducing opioid
misuse, although additional controlled trials are needed to
empirically establish this effect.
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